In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
Irloxacin (E-3432) is a new quinolone derivative. In this study, the activity of irloxacin was compared with that of nalidixic acid, norfloxacin and ciprofloxacin against strains of clinical isolates. Irloxacin showed greater in vitro activity than nalidixic acid, similar activity to norfloxacin and lower activity than ciprofloxacin. Against Staphylococcus, the MIC range of E-3432 was 0.06-1 mg/l, better than the other compounds studied.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D055598:Chemical Phenomena; D002621:Chemistry; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D024841:Fluoroquinolones; D009268:Nalidixic Acid / Q000494:pharmacology; D009643:Norfloxacin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D011804:Quinolines; C046067:pirfloxacin; D009268:Nalidixic Acid; D002939:Ciprofloxacin; D009643:Norfloxacin